Prevalence and Characteristics of Hyperferritinemia in Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Meta‐Analysis

HF is present in approximately one in four patients with MASLD and identifies a subgroup with more severe metabolic dysfunction and liver injury. These data highlight SF as a simple, accessible biomarker that may help identify higher-risk MASLD phenotypes.